July 24, 2020 -- Exonbio debuted its SARS-CoV-2 nucleocapsid recombinant monoclonal antibodies (mAbs) for the global in vitro diagnostics and research communities.
Since the start of the pandemic, Exonbio has developed SARS-CoV-2 recombinant rabbit antibodies using its proprietary single plasma cell interrogation (SPIN) platform. The firm has screened hundreds of clones of rabbit mAbs by surface plasmon resonance with Biacore 3000 and identified high-affinity clones against the recombinant full-length nucleocapsid protein of SARS-CoV-2.
Researchers identified 12 clones with a half maximal effective concentration (EC50) of less than 1 ng/mL, with the most potent clone being 6F2 at EC50 of 0.37 ng/mL (2.5 pM). Epitope mapping pointed to at least five well-separated epitopes so there are multiple choices for selecting the pairs for sandwich enzyme-linked immunosorbent assay (ELISA). In addition, there are choices for other applications that require a pair of antibodies as well.